Connect with us


Roche gantenerumab improves biomarkers in inherited form of Alzheimer’s disease – PMLiVE

However, anti-amyloid antibody did not show evidence of cognitive benefit for patients



Article feature image

A new study, published in Nature Medicine, has showed that Roche’s investigational candidate gantenerumab led to improvements in a number of biomarkers in patients with an inherited form of Alzheimer’s disease.
In the DIAN-TU-001 trial, researchers from…

Click here to view the original article.

Continue Reading


You might also like ...

Article feature image
‘Very difficult’: 69,000 jabs a day needed to reach NSW’s 6 million target – Sydney Morning Herald
COVID-19 update 4 August 2021 – WA Health